大麻与健康研究计划将帮助把药用大麻纳入医疗保健中

IF 58.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Nature Medicine Pub Date : 2024-10-22 DOI:10.1038/s41591-024-03288-w
Johannes Thrul, Ryan Vandrey
{"title":"大麻与健康研究计划将帮助把药用大麻纳入医疗保健中","authors":"Johannes Thrul, Ryan Vandrey","doi":"10.1038/s41591-024-03288-w","DOIUrl":null,"url":null,"abstract":"<p>In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing &lt;0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited<sup>1</sup>, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice<sup>2</sup>, and medicinal cannabis use is poorly documented in electronic medical records (EMRs)<sup>3</sup>. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use<sup>4</sup>.</p><p>With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased<sup>5</sup>. Products vary in chemical composition<sup>6</sup>, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare\",\"authors\":\"Johannes Thrul, Ryan Vandrey\",\"doi\":\"10.1038/s41591-024-03288-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing &lt;0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited<sup>1</sup>, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice<sup>2</sup>, and medicinal cannabis use is poorly documented in electronic medical records (EMRs)<sup>3</sup>. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use<sup>4</sup>.</p><p>With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased<sup>5</sup>. Products vary in chemical composition<sup>6</sup>, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.</p>\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-024-03288-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-024-03288-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在美国,有超过 550 万名注册患者参加了州政府监管的药用大麻计划,许多人将大麻产品(源自干重含 0.3% δ-9-四氢大麻酚(THC)的大麻)用于治疗目的。然而,对非药用大麻产品的临床研究仍然有限1 ,医疗服务提供者在将药用大麻纳入其实践方面感到培训不足2 ,电子病历(EMR)中对药用大麻的使用记录很少3。 这些问题凸显了对有关药用大麻使用影响的患者层面数据的需求4。随着美国一些州的大麻零售合法化,消费者可获得的大麻产品种类大幅增加5。产品的化学成分6 、剂量和预期给药途径各不相同,所有这些都会影响临床效果、安全性和滥用责任,在临床决策中应加以考虑。大麻产品种类繁多,使用的术语定义不清,给评估药用大麻对健康的影响造成了困难。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare

In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited1, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice2, and medicinal cannabis use is poorly documented in electronic medical records (EMRs)3. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use4.

With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased5. Products vary in chemical composition6, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nature Medicine
Nature Medicine 医学-生化与分子生物学
CiteScore
100.90
自引率
0.70%
发文量
525
审稿时长
1 months
期刊介绍: Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
期刊最新文献
Using tumor DNA methylomes to predict cancer metastasis to the brain Obesity predisposes to specific cancer driver mutations Citizen science as an instrument for women’s health research Author Correction: Subclassification of obesity for precision prediction of cardiometabolic diseases Limiting babies’ sugar intake protects them against chronic diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1